Why the study?
Deep vein thrombosis of the lower extremities is more common in older patients, but anticoagulant therapy carries a higher risk of hemorrhagic complications.
Does the type of anticoagulant therapy affect the frequency of hemorrhagic complications in elderly patients with deep vein thrombosis?
Observational (n=140)
Does the type of anticoagulant therapy affect the frequency of hemorrhagic complications in elderly patients with deep vein thrombosis?
In elderly patients with deep vein thrombosis, apixaban is associated with a lower incidence of clinically relevant non-major bleeding compared to vitamin K antagonists and rivaroxaban.
May support apixaban preference in elderly DVT for lower bleeding risk; hypothesis-generating and requires randomized confirmation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Чечулова et al. (2021) conducted an observational in Deep vein thrombosis (n=140). Anticoagulant therapy (apixaban, rivaroxaban, or heparin/VKA) vs. Between-group comparison was evaluated on Frequency and severity of hemorrhagic complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: